Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial.

We conducted a randomized, double-blind, placebo-controlled trial to assess the atrophogenicity of tacrolimus ointment. In a combined group of atopic dermatitis patients (n = 14) and healthy volunteers (n = 12), 0.3% tacrolimus, 0.1% tacrolimus, betamethasone-valerate, and a vehicle control were applied in a randomized order to nonsymptomatic, 4 cm x 4 cm regions of abdominal skin. After 7 d of treatment under occlusion, the carboxy- and amino-terminal propeptides of procollagen I (PICP, PINP) and the amino-terminal propeptide of procollagen III (PIIINP) were measured from suction blister fluid with specific radioimmunoassays. In addition, ultrasound measurements of skin thickness were taken. Betamethasone-treated areas showed median PICP, PINP, and PIIINP concentrations of 17.0%, 17.6%, and 39.5% of the vehicle control at the end of the treatment period, respectively, whereas the 0.1% and 0.3% tacrolimus-treated areas showed median concentrations of approximately 100% of the vehicle control (p < 0.001). Betamethasone was also the only treatment to reduce skin thickness; the median decrease in skin thickness was 7.4% relative to 0.1% tacrolimus, 7.1% relative to 0.3% tacrolimus, and 8.8% relative to the vehicle control (p < 0.01). Results for atopic dermatitis patients and healthy volunteers were similar. These findings suggest that tacrolimus does not cause skin atrophy.

[1]  G. Rajka,et al.  Grading of the severity of atopic dermatitis. , 1989, Acta dermato-venereologica. Supplementum.

[2]  H. Nakagawa,et al.  Tacrolimus ointment for atopic dermatitis , 1994, The Lancet.

[3]  K. Ohara,et al.  Comparison of FK506 (Tacrolimus) and Glucocorticoid Ointment on Dermal Atrophogenicity in Rats , 1997 .

[4]  S. Reitamo,et al.  Delayed hypersensitivity to topical corticosteroids. , 1986, Journal of the American Academy of Dermatology.

[5]  J. R. Scholtz MANAGEMENT OF ATOPIC DERMATITIS. , 1965, California medicine.

[6]  P. Dykes,et al.  An appraisal of the methods used in the assessment of atrophy from topical corticosteroids , 1979, The British journal of dermatology.

[7]  P. Payne,et al.  Skin thickness measurement by pulsed ultrasound; its reproducibility, validation and variability , 1982, The British journal of dermatology.

[8]  P. Sprent,et al.  Applied nonparametric statistical methods , 1988 .

[9]  Johannes Ring,et al.  Handbook of Atopic Eczema , 1991, Springer Berlin Heidelberg.

[10]  S. Todo,et al.  Tacrolimus in solid organ transplantation , 1996 .

[11]  J. Risteli,et al.  Recovery of human skin collagen synthesis after short‐term topical corticosteroid treatment and comparison between young and old subjects , 1996, The British journal of dermatology.

[12]  Douglas G. Altman,et al.  Statistics with confidence: Confidence intervals and statistical guidelines . , 1990 .

[13]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.

[14]  M. Okuhara,et al.  FK 506: historical perspectives. , 1991, Transplantation proceedings.

[15]  J. Meingassner,et al.  Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? , 1992, The Journal of investigative dermatology.

[16]  T. Bieber,et al.  A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. , 1997, The New England journal of medicine.

[17]  T. Ruzicka Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study , 1995 .

[18]  U Kiistala,et al.  Suction blister device for separation of viable epidermis from dermis. , 1968, The Journal of investigative dermatology.